#### FLUIDIGM CORP

Form 4

February 16, 2011

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB ,

Number: 3235-0287

**OMB APPROVAL** 

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person <u>\*</u> EDB Investments Pte Ltd.

2. Issuer Name **and** Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

FLUIDIGM CORP [FLDM]

(Check all applicable)

210201 10 11/1 1/ 1/00 01

(First)

(Street)

(State)

3. Date of Earliest Transaction (Month/Day/Year)

\_\_\_\_ Director
\_\_\_\_ Officer (give title

\_\_X\_\_ 10% Owner \_\_\_\_ Other (specify

20 BIOPOLIS WAY #09-01, 02/15/

(Middle)

(Zip)

02/15/2011

below) below)
6. Individual or Joint/Group Filing(Check

4. If Amendment, Date Original Filed(Month/Day/Year)

Applicable Line)

\_\_\_ Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

#### **CENTROS, U0 138668**

		Tuble 1 Tion Berryante Securiaes Required, Disposed of, or Be							y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired (A) Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			5. Amount of 6. Securities Ownership Beneficially Form: Owned Direct (D) Following or Indirect Reported (I)	Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					(A) or		Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
			Code V	Amount	(D)	Price	(Ilisti. 5 and 4)		
Common Stock	02/15/2011		C(1)	1,047,955	A	<u>(2)</u>	1,047,955	D (3) (4)	
Common Stock	02/15/2011		C(5)	623,531	A	<u>(2)</u>	1,671,486	D (3) (4)	
Common Stock	02/15/2011		C(5)	128,025	A	(2)	1,799,511	D (4) (6)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

#### Edgar Filing: FLUIDIGM CORP - Form 4

# $\label{thm:convertible} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

I	Title of Derivative Security Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of stiorDerivative Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration Date (Month/Day/Year) ) or (D)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
l	Series E Preferred Stock	<u>(2)</u>	02/15/2011		C		1,047,955	<u>(7)</u>	<u>(7)</u>	Common Stock	1,047,95
l	Series D Preferred Stock	(2)	02/15/2011		C		623,531	<u>(8)</u>	<u>(8)</u>	Common Stock	623,531
l	Series C Preferred Stock	<u>(2)</u>	02/15/2011		C		128,025	(8)	(8)	Common Stock	128,025

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Nauress	Director	10% Owner	Officer	Other		
EDB Investments Pte Ltd. 20 BIOPOLIS WAY #09-01 CENTROS, U0 138668		X				
Biomedical Sciences Investment Fund Pte Ltd. 20 BIOPOLIS WAY #09-01 CENTROS, U0 138668		X				
SINGAPORE BIO INNOVATIONS PTE LTD 250, NORTH BRIDGE ROAD #20-02 RAFFLES CITY TOWER SINGAPORE, U0 179101		X				

### **Signatures**

Stephanie Sterling of Gibson, Dunn & Crutcher LLP, attorney-in-fact for EDB Investments Pte Ltd	02/16/2011
**Signature of Reporting Person	Date
Stephanie Sterling of Gibson, Dunn & Crutcher LLP, attorney-in-fact for Biomedical Sciences Investment Fund Pte Ltd	02/16/2011
**Signature of Reporting Person	Date
Stephanie Sterling of Gibson, Dunn & Crutcher LLP, attorney-in-fact for Singapore Bio Innovations Pte Ltd	02/16/2011

Reporting Owners 2

\*\*Signature of Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares of Common Stock issued upon conversion of shares of Series E Preferred Stock on a 1-for 1.300053676865 basis.
- (2) Not applicable.
- (3) Biomedical Sciences Investment Fund Pte Ltd is the record holder of the securities reported.
  - EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and
- (4) dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, one of the Issuer's directors is a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
- (5) Represents shares of Common Stock issued upon the conversion of shares of Series C Preferred Stock and Series D Preferred Stock on a 1-for-1 basis.
- (6) Singapore Bio-Innovations Ptd Ltd is the record holder of the securities reported.
- (7) Each share of Series E Preferred Stock converted into 1.300053676865 share of Common Stock on February 15, 2011 and has no expiration date.
- (8) Each share of Series C Preferred Stock or Series D Preferred Stock converted into one share of Common Stock on February 15, 2011 and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3

Date